éå»1ã¶æéã«Ascendis Pharma A/Sã«å¯ŸããŠè©äŸ¡ãåºããã¢ããªã¹ã20åã«åºã¥ãããŒã¿ã
仿ãASNDã¯10ä»¶ã®ãè²·ããã0ä»¶ã®ãäžç«ïŒããŒã«ãïŒãã0ä»¶ã®ã売ããè©äŸ¡ãç²åŸããŸãããçŽè¿1ã¶æã«ãããASNDã®ã¢ããªã¹ãå¹³åç®æšæ ªäŸ¡ã¯316.564ã§ãã
ã¢ããªã¹ãäºæ³ã«ãããšãFY2026Q2ã«çºè¡šãããEPS 3.678ã«ç¶ããASNDã®FY2026Q3ã®EPSã¯1.076ã«éããèŠéãã§ããçºè¡šãããå®çžŸå€ãšäºæ³ãæ¯èŒããŠãåçæ§ã®æšç§»ã確èªããŸãããã
åžå Žäºæ³ã¯ USD 3.68 ã§ããããAscendis Pharma A/SASND ã®åååæã®äžæ ªåœããå©ç (EPS) 㯠USD 11.79 ã§ãããæ¬¡ã®ååæã® EPS 㯠USD 1.08 ãšäºæ³ãããŸãã